Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods
Afrischolar Discovery · 23.11.2023
DOI: 10.60787/wapcp-26-2-95 ↗Kurz gefasst
Fachartikel in der Zeitschrift Afrischolar Discovery, erschienen am 23.11.2023. Verfasst von Ogochukwu Ukamaka Amaeze und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Generic medicines must be therapeutic equivalents with the innovator brand before substitution is appropriate.
Objective
This study was carried out to evaluate the in vitro equivalence of valsartan (a BCS Class III drug) tablets under Biowaiver conditions.
Methods
Physicochemical parameters were assessed in accordance with BP and USP specifications. Therapeutic equivalence of the innovator and commonest generic brands were investigated using in vitro methods.
Results
The tested valsartan brands investigated complied with Compendia specifications for tablets. Valsartan tablets were not very rapidly dissolving as per WHO Biowaiver testing specifications. Both test and reference products were poorly soluble in acidic medium (pH 1.2), while 85% of the drug was released at 15 minutes in pH 6.8. Dissolution profiles of the test and innovator brands were similar at pH 1.2 and 6.8 (f2: 65 and 69 respectively), and dissimilar at pH 4.5 (f2: 30). The generic valsartan tablets evaluated in this study showed pharmaceutical equivalence with the innovator brand. The test and reference products were not however very rapidly dissolving as required for BCS Class III drugs.
Conclusion
The valsartan tablet brands tested did not meet WHO BCS-based biowaiver conditions. In vivo bioequivalence studies are recommended to ascertain therapeutic equivalence and interchangeability.
Schlagwörter
Zitieren
APA
Amaeze, O. U., Oyetunde, O., O., Akinleye, M. O., Oluwole, & O., D. (2023). Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods. Afrischolar Discovery. https://doi.org/10.60787/wapcp-26-2-95
Vancouver
Amaeze OU, Oyetunde, O. O, Akinleye MO, Oluwole, O. D. Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods. Afrischolar Discovery. 2023. doi:10.60787/wapcp-26-2-95
BibTeX
@article{Amaeze2023,
author = {Amaeze, Ogochukwu Ukamaka and Oyetunde and O., Olubukola and Akinleye, Moshood Olusola and Oluwole and O., David},
title = {Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods},
journal = {Afrischolar Discovery},
year = {2023},
doi = {10.60787/wapcp-26-2-95}
}
EUVIMED